June 24, 2025
ACHP calls on Congress to increase access to biosimilars by redefining interchangeability requirements and addressing outdated regulations, skewed incentives and PBM practices that intentionally slow their adoption.
New from ACHP:
- ACHP Statement on Budget Reconciliation Bill
- ACHP Recommendations on Prescription Drug Machine-Readable File Requirement in Coverage Final Rule
- ACHP Opposes Senate Reconciliation Bill That Threatens Coverage for Millions
- ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
- GLP-1s Are Not A Silver Bullet
- Local Health Plans Meet Community Needs with Affordable, Accessible Vaccines
